

November 12, 2008

PRESSRELEASE

Over 350 smokers vaccinated to prevent smoking relapse in Phase II clinical trial

The last of 355 smokers has now been enrolled into a phase II clinical trial with Niccine[®], a nicotine vaccine. The primary goal of this multi-center study is to demonstrate prevention of smoking relapse after successfully having quit smoking.

There is a strong global medical need for new methods that prevent smokers from beginning to smoke again and to achieve persistent abstinence from smoking. It is known that 70 - 80 % of those who quit smoking relapse into smoking within 12 months. Niccine[®] is designed to prevent future relapses in previous smokers and in smokers that plan to quit smoking in the near future.

Independent Pharmaceutica AB

Independent Pharmaceutica AB is a Swedish research and development company based at Karolinska Institutet in Stockholm. The company was founded in 1997 by Professor Torgny Svensson with the idea to combine world class expertise in research and development at the Karolinska Institutet with other experts in the fields of psychotropic drugs, drug dependency, smoking cessation and vaccine technology to develop a vaccine against nicotine addiction. The company has patents granted e.g. in the US and Europe.

For further information, please contact

Lena Degling Wikingsson CEO

Mobile: +46 70 790 0207

Phone: +46 8 508 84493 E-mail: degling-wikingsson@ipab.biz

Statements in this press release that are not strictly historical, are "forward-looking" statements, which involve a high degree of risk and uncertainty. Such statements are only predictions, and the actual events or results may differ materially from those projected in such forward statements.